SCHEMBL4771203

SCHEMBL4771203

CS(=O)(=O)N(Cc1ccccc1Cl)c1ccc(C(=O)NCC(O)c2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.60
ALDH1A1 P00352 6/20 0.57
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
MAPT P10636 1/20 0.50
KMT2A Q03164 2/20 0.47
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767994 0.93 GAA (0.53) GAAALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4767999 0.93 GAA (0.53) GAAALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4776615 0.84 GAA (0.68) GAAALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL4772417 0.82 GAA (0.66) GAAALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL4777696 0.82 GAA (0.66) GAAALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL4768069 0.81 GAA (0.64) GAAALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL4777288 0.81 GAA (0.61) GAAALDH1A1MAPTKMT2ARECQL
SCHEMBL4770963 0.80 GAA (0.63) GAAALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL14497659 0.80 GAA (0.59) GAAALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL4774743 0.79 ALDH1A1 (0.60) GAAALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885ALDH1A1 2159/4885SMN1; SMN2 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.